• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

SenzaGen

5.84 SEK

+4.29 %

Less than 1K followers

SENZA

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+4.29 %
+3.18 %
+14.06 %
-3.95 %
-3.63 %
+8.15 %
-45.67 %
-64.50 %
-86.18 %

Senzagen is a medical technology company. The company develops and carries out genomic in vitro tests, which means that the toxicological ability of various chemicals is not tested on animals but instead in test tubes. The company has developed a technological platform that is used to study the impact of substances produced by actors in the pharmaceutical, cosmetics, and chemical industries. Research and development take place from the head office in Lund.

Read more
Market cap
189.85M SEK
Turnover
829.28 SEK
Revenue
57.97M
EBIT %
-20.05 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
20/8
2026

Interim report Q2'26

5/11
2026

Interim report Q3'26

18/2
2027

Annual report '26

Press release6/9/2026, 5:30 AM

SenzaGens dotterbolag erhåller två ordrar inom djurfri testning till ett totalt värde om 2,4 MSEK

SenzaGen
Press release6/9/2026, 5:30 AM

SenzaGen’s subsidiary receives two orders within non-animal testing with a total value of SEK 2.4 million

SenzaGen
Press release6/5/2026, 5:30 AM

EU presenterar färdplan för att fasa ut djurförsök – stärker SenzaGens långsiktiga marknadspotential

SenzaGen

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release6/5/2026, 5:30 AM

EU presents roadmap to phase out animal testing – strengthens SenzaGen’s long-term market potential

SenzaGen
Regulatory press release5/12/2026, 1:25 PM

Kommuniké från årsstämma i SenzaGen AB den 12 maj 2026

SenzaGen
Regulatory press release5/12/2026, 1:25 PM

Report from AGM of SenzaGen AB on 12 May 2026

SenzaGen
SenzaGen, Webcast, Q1'26
Webcast5/12/2026, 7:00 AM

SenzaGen, Webcast, Q1'26

SenzaGen
Regulatory press release5/12/2026, 5:30 AM

SenzaGens delårsrapport januari-mars 2026 | Tillväxt med 10 procent tillsammans med ökad uppmärksamhet för djurfria metoder

SenzaGen
Regulatory press release5/12/2026, 5:30 AM

SenzaGen’s interim report January–March 2026 | 10% sales growth alongside increased attention to non-animal methods

SenzaGen
Press release5/5/2026, 7:30 AM

Inbjudan till presentation av SenzaGens delårsrapport januari-mars 2026

SenzaGen
Press release5/5/2026, 7:30 AM

Invitation to the presentation of SenzaGen's January-March 2026 interim report

SenzaGen
Regulatory press release4/21/2026, 7:00 AM

SenzaGen’s Annual Report 2025 published

SenzaGen
Regulatory press release4/21/2026, 7:00 AM

SenzaGen publicerar årsredovisningen för 2025

SenzaGen
Press release4/15/2026, 5:30 AM

SenzaGens dotterbolag erhåller strategiskt viktig order

SenzaGen
Press release4/15/2026, 5:30 AM

SenzaGen’s subsidiary receives strategically important order

SenzaGen
Regulatory press release4/8/2026, 6:30 AM

Kallelse till årsstämma i SenzaGen AB (Publ)

SenzaGen
Regulatory press release4/8/2026, 6:30 AM

NOTICE OF ANNUAL GENERAL MEETING OF SENZAGEN AB (Publ)

SenzaGen
Press release3/30/2026, 5:30 AM

SenzaGen vinner ny global kosmetika-koncern som kund

SenzaGen
Press release3/30/2026, 5:30 AM

SenzaGen wins new global cosmetics group as customer

SenzaGen
Press release3/17/2026, 6:30 AM

SenzaGen presenterar stark GARD®skin-data på världens största toxikologikonferens tillsammans med ledande industripartners

SenzaGen